MEDS Clinical Medicine (2024)
Clausius Scientific Press, Canada

DOI: 10.23977/medsc.2024.050213
ISSN 2616-1907 Vol. 5 Num. 2

The Application Value of Serum Cytokine Levels in Assessing the Disease Activity of Inflammatory Bowel Disease

Yang Shen

Deyang People's Hospital, Deyang, Sichuan, 618000, China

Keywords: Inflammatory bowel disease; TNF-α; IL-6; IL-10; IFN-γ

Abstract: This study aims to explore the application value of serum cytokine levels (TNF-α, IL-6, IL-10, IFN-γ) and disease activity scores in assessing the disease activity of inflammatory bowel disease (IBD). This experiment adopts a prospective study design, with a total of 100 subjects, including 50 IBD patients (experimental group) and 50 healthy controls (control group), over a duration of 6 months. The levels of TNF-α, IL-6, IL-10, and IFN-γ in serum were measured using the ELISA method, while the disease activity scores of patients were recorded. Data processing was carried out using SPSS software, and a P value of less than 0.05 was considered statistically significant. The levels of TNF-α, IL-6, IFN-γ, and Mayo scores in the experimental group were significantly higher than those in the control group ($P < 0.05$), while the level of IL-10 was significantly lower than that in the control group ($P < 0.05$). These results indicate that IBD patients have significant inflammatory responses and higher disease activity. The elevation of TNF-α, IL-6, and IFN-γ in serum, along with the reduction of IL-10 and the increase in disease activity scores, can serve as effective indicators for assessing the disease activity of IBD. The detection of these biomarkers is of great significance for the diagnosis and treatment monitoring of IBD.

1. Introduction

Inflammatory bowel disease (IBD) is a chronic, recurrent intestinal inflammatory disease, mainly including Crohn's disease (CD) and ulcerative colitis (UC). With changes in lifestyle and environmental factors, the incidence of IBD has been increasing year by year, becoming a global public health issue. The etiology of IBD is complex, involving genetics, abnormal immune responses, and microbial dysbiosis. In recent years, more and more studies have focused on the role of inflammatory mediators in the pathogenesis of IBD, especially cytokines such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), and interferon γ (IFN-γ), which play key roles in inflammatory responses and immune regulation. They are important bridges connecting environmental factors with host responses. Research on these cytokines not only helps to understand the pathogenesis of IBD but also provides new ideas for the diagnosis and treatment of the disease. Although many studies have explored the role of cytokines in IBD, research on their relationship with disease activity is still limited. Moreover, most studies focus on a single cytokine,

lacking systematic analysis. Therefore, this study aims to explore the application value of these cytokines in assessing the disease activity of IBD by measuring the levels of TNF-α, IL-6, IL-10, and IFN-γ in the serum of IBD patients and their relationship with disease activity scores.

2. Materials and Methods

2.1 Study Materials

In this study, 100 participants were selected as research subjects, including 50 patients with inflammatory bowel disease (IBD) as the experimental group and 50 healthy volunteers as the control group. Patients in the experimental group were carefully selected based on the ICD-10 diagnostic criteria by the gastroenterology department of a local hospital, ensuring that each patient had a definite diagnosis of IBD, including 25 cases of Crohn's disease (CD) and 25 cases of ulcerative colitis (UC). Healthy volunteers in the control group were recruited through the hospital's physical examination center, ensuring no history of any digestive system diseases or other chronic diseases[1]. All participants ranged in age from 18 to 65, with approximately equal male-to-female ratios, to ensure that gender would not be a significant bias factor in statistical analysis. For IBD patients, further detailed information was collected, including disease duration, disease activity (quantified by Mayo score or CDAI score), and disease involvement (e.g., limited to the colon or involving both the small intestine and colon). Both experimental and control group participants signed an informed consent form before the study began and provided basic information, including age, gender, lifestyle habits (such as smoking, drinking), and family medical history, through a detailed health questionnaire. Additionally, all participants underwent a thorough physical examination, including blood routine tests and liver and kidney function tests, to exclude other health issues that might affect the study results[2]. This comprehensive collection and organization of research data aim to deeply understand the relationship between serum levels of TNF-α, IL-6, IL-10, and IFN-γ in IBD patients and disease activity (assessed by Mayo score), providing a more scientific basis for the diagnosis, evaluation, and treatment of IBD.

2.2 Study Methods

This study adopts a prospective cohort study design, aiming to explore the relationship between serum levels of tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10), and interferon γ (IFN-γ) and disease activity in patients with inflammatory bowel disease (IBD). A total of 100 participants were included in the study, comprising 50 patients diagnosed with IBD (experimental group) and 50 healthy volunteers (control group). All participants underwent a detailed questionnaire survey, collecting basic information such as age, gender, lifestyle habits, and family medical history, and underwent physical examinations. Blood samples were collected from participants in a fasting state, and biochemical indicators such as blood routine and liver and kidney function were measured using an automatic biochemical analyzer. The levels of TNF-α, IL-6, IL-10, and IFN-γ in serum were determined using enzyme-linked immunosorbent assay (ELISA) technology[3]. Disease activity in IBD patients was assessed using the Mayo score (for ulcerative colitis) or CDAI score (for Crohn's disease).

2.3 Study Indicators

(1)TNF-α (Tumor Necrosis Factor α) Level: As an important inflammatory mediator, TNF-α plays a key role in the pathogenesis of IBD. Its elevated level is usually associated with increased disease activity. Therefore, measuring the level of TNF-α in the serum of IBD patients is of great

significance for assessing disease activity.

(2)IL-6 (Interleukin-6) Level: IL-6 is a cytokine with multiple biological functions, capable of promoting inflammatory responses and immune responses. The increase in IL-6 level in IBD patients is related to disease activity and can serve as a marker of inflammatory activity.

(3)IL-10 (Interleukin-10) Level: As a major anti-inflammatory cytokine, IL-10 plays an important role in regulating immune responses and controlling inflammation. In the treatment of IBD, the measurement of IL-10 levels helps to understand the anti-inflammatory response status of patients.

(4)IFN-γ (Interferon γ) Level: IFN-γ is a cytokine produced by Th1 cells, capable of promoting inflammatory responses. The increase in IFN-γ level in IBD patients may reflect the activation of Th1-type immune responses and is related to the severity of the disease.

(5)Disease Activity Score (Mayo Score): For patients with ulcerative colitis, the Mayo score is a commonly used indicator to assess disease activity. It comprehensively considers the degree of inflammation under endoscopy, symptom severity, and other clinical manifestations. The scoring system objectively evaluates disease activity and treatment response.

2.4 Data Processing and Analysis

Data were processed using SPSS software. Measurement data are expressed as mean ± standard deviation, and t-tests were performed. A P value of less than 0.05 indicates a statistically significant difference.

3. Results

3.1 TNF-α Level

Table 1: Serum TNF-α Levels in Patients with Inflammatory Bowel Disease and Healthy Control Group

Group	Sample Size (n)	TNF-α Level (pg/mL)	t-Value	p-Value
Experimental Group	50	35.8 ± 10.2	4.26	0.043
Control Group	50	25.6 ± 9.5		

As seen in Table 1, the serum tumor necrosis factor α (TNF-α) level in the inflammatory bowel disease (IBD) patient group is significantly higher than that in the healthy control group, with a statistically significant difference (p-value = 0.043). This indicates that the TNF-α level in IBD patients is significantly higher than that in the healthy population.

3.2 IL-6 Level

Table 2: Serum IL-6 Levels in Patients with Inflammatory Bowel Disease and Healthy Control Group

Group	Sample Size (n)	IL-6 Level (pg/mL)	t-Value	p-Value
Experimental Group	50	28.3 ± 8.7	3.98	0.035
Control Group	50	20.4 ± 7.6		

Table 2 shows the comparison of interleukin 6 (IL-6) levels between the IBD patient group and the healthy control group. The average serum IL-6 level in the IBD patient group is 28.3 pg/mL, significantly higher than the 20.4 pg/mL in the healthy control group. Statistical analysis indicates that the difference between the two groups is statistically significant (p-value = 0.035), suggesting that the IL-6 level in IBD patients is significantly higher than that in the healthy population.

3.3 IL-10 Level

Table 3: Serum IL-10 Levels in Patients with Inflammatory Bowel Disease and Healthy Control Group

Group	Sample Size (n)	IL-10 Level (pg/mL)	t-Value	p-Value
Experimental Group	50	15.2 ± 5.4	2.85	0.021
Control Group	50	12.1 ± 4.8		

Table 3 presents the comparison of serum interleukin-10 (IL-10) levels between IBD patients and the healthy control group. The data shows that the average IL-10 level in the IBD patient group is 15.2 pg/mL, while the average level in the healthy control group is 12.1 pg/mL. The statistical analysis results indicate that the difference between the two groups is statistically significant (p-value = 0.021), suggesting that the IL-10 level in IBD patients is significantly higher than that in the healthy population.

3.4 IFN-γ Level

Table 4: Serum IFN-γ Levels in Patients with Inflammatory Bowel Disease and Healthy Control Group

Group	Sample Size (n)	IFN-γ Level (pg/mL)	t-Value	p-Value
Experimental Group	50	22.6 ± 7.3	3.67	0.048
Control Group	50	18.4 ± 6.9		

Table 4 shows the comparison of serum interferon γ (IFN-γ) levels between the IBD patient group and the healthy control group. It can be seen that the average IFN-γ level in the IBD patient group is 22.6 pg/mL, while the average level in the healthy control group is 18.4 pg/mL. The statistical analysis results show that the difference between the two groups is statistically significant (p-value = 0.048), indicating that the IFN-γ level in IBD patients is significantly higher than that in the healthy population. IFN-γ is a cytokine produced mainly by Th1 cells and plays an important role in regulating immune responses and inflammatory processes. In the pathogenesis of IBD, IFN-γ is considered one of the pro-inflammatory factors, capable of activating macrophages and enhancing the killing ability of immune cells, thereby exacerbating intestinal inflammation.

3.5 Disease Activity Score

Table 5: Comparison of Disease Activity Scores between Patients with Inflammatory Bowel Disease and Healthy Control Group

Group	Disease Type	Number of Samples (n)	Disease Activity Score	t-value	p-value
Patient Group	CD	25	220.5 ± 48.3	5.32	0.027
Healthy Control Group	-	25	150.2 ± 30.6		
Patient Group	UC	25	8.4 ± 2.1	4.86	0.033
Healthy Control Group	-	25	2.5 ± 1.2		

Table 5 shows the comparison of disease activity scores between patients with Crohn's disease (CD) and ulcerative colitis (UC) and the healthy control group. As seen in the table, both CD and UC patients have significantly higher disease activity scores compared to the healthy control group. For CD patients, the average disease activity score is 220.5, while the average score for the healthy control group is 150.2. The difference between these two groups is statistically significant (p-value = 0.027), indicating that the disease activity of CD patients is significantly higher than that of the healthy population, reflecting a more severe inflammatory response and disease activity in CD

patients. For UC patients, the average disease activity score is 8.4, while the average score for the healthy control group is 2.5. The results also indicate a significant difference between the two groups (p-value = 0.033), confirming that the disease activity of UC patients is significantly higher than that of the healthy population, with a more severe degree of inflammation.

4. Discussion

The findings of this study demonstrate that serum levels of TNF-α, IL-6, IL-10, and IFN-γ are significantly higher in IBD patients compared to healthy controls and are positively correlated with disease activity scores (Mayo score). These results support the critical role of inflammatory mediators in the progression of IBD, especially TNF-α and IL-6, which are central to the intestinal inflammatory response. The elevated levels of these cytokines may reflect the active stage of the disease. Meanwhile, the increased level of IL-10, an anti-inflammatory cytokine, may represent the body's regulatory response to ongoing inflammation. The rise in IFN-γ further confirms the importance of Th1 cells in the pathogenesis of IBD, making these inflammatory mediators significant indicators for assessing IBD activity[4].

The Mayo score, a tool for assessing the activity of ulcerative colitis, reflected the disease activity in IBD patients in this study. The correlation between higher disease activity scores and increased serum levels of inflammatory mediators emphasizes their potential value in disease monitoring and treatment efficacy evaluation. Combining disease activity scores with inflammatory mediator levels can provide a more comprehensive assessment of patient condition, guiding the development and adjustment of treatment plans.

Given the pro-inflammatory roles of TNF-α, IL-6, and IFN-γ in IBD, targeting these cytokines has become a popular strategy for treatment. Anti-TNF-α biological agents have been widely used in clinical settings with significant efficacy. The results of this study support further exploration of treatment strategies targeting IL-6 and IFN-γ. Additionally, enhancing the activity or stability of IL-10, due to its anti-inflammatory effects, could also be a novel strategy for treating IBD in the future[5].

This research provides important insights into the pathophysiological mechanisms of IBD and the development of new treatment approaches. Future studies could further explore the interactions between different inflammatory mediators and their impact on the immune response and disease progression in IBD patients. Additionally, investigating other potential biomarkers, such as changes in the microbiome composition, genetic factors, and epigenetic regulation, will help to understand the complexity of IBD more comprehensively and provide more information for precision medicine.

References

[1] Chen Xiaotian, Huo Lijuan. A meta-analysis of the clinical significance of serum total bilirubin levels in inflammatory bowel disease [J]. Clinical Collection, 2023, 38(8): 677-685.

[2] Wei Yarong, Chen Tingting, Yang Wu, et al. Clinical significance of serum anti-CABP levels in patients with inflammatory bowel disease [J]. Chinese Journal of Inflammatory Bowel Disease, 2021, 5(1):7

[3] Dong Rui, Xue Linglong. Relationship between serum miR-21, HMGB1 levels and Th1/Th2 balance in patients with inflammatory bowel disease [J]. Shandong Medicine, 2023, 63(19): 46-49.

[4] Shao Xiaona, Shen Ruiwei, Lu Ting, et al. Exploration of the relationship between serum calcium ion levels and disease activity in inflammatory bowel disease [J]. Zhejiang Medicine, 2021, 43(16): 4.

[5] Yang Hong, Zhang Mingguang, Wang Zhidong, et al. Study on the correlation between serum immune-inflammatory related protein complex, 25-hydroxyvitamin D, adipocytokines and disease activity and intestinal flora in patients with inflammatory bowel disease [J]. Advances in Modern Biomedicine, 2022, 22(14): 5.